TBXAS1: A Potential Drug Target and Biomarker for Cytochrome P450 Enzyme

Target Name: TBXAS1

NCBI ID: G6916

TBXAS1

TBXAS1: A Potential Drug Target and Biomarker for Cytochrome P450 Enzyme

The human cytochrome P450 (CYP) enzyme is a crucial metabolizer that is involved in the metabolism of a wide variety of drugs, including many statins, benzodiazepines, and opioids. Cytochrome P450 enzymes are also involved in the production of other metabolites that can have both beneficial and detrimental effects on the body. One of the most well-studied cytochrome P450 enzymes is TBXAS1 (Toxin-Inducible X-Responsive Enzyme, family 5, subfamily A, polypeptide 1). This enzyme is a potential drug target and biomarker for the inhibition of cytochrome P450 enzyme-mediated drug responses.

TBXAS1 is a cytochrome P450 enzyme that is expressed in various tissues throughout the body, including the liver, kidney, and intestine. This enzyme is responsible for metabolizing a wide variety of drugs, including many statins, benzodiazepines, and opioids. It is also involved in the production of other metabolites that can have both beneficial and detrimental effects on the body. For example, TBXAS1 has been shown to metabolize statins to inactive compounds, which may reduce the efficacy of these drugs. Additionally, TBXAS1 has been shown to contribute to the production of unwanted metabolites of opioids, which can have adverse effects on the body.

The inhibition of cytochrome P450 enzyme-mediated drug responses is a promising approach for the development of new treatments for a wide range of diseases. drugs that can inhibit the activity of TBXAS1 have been shown to be effective in treating a variety of conditions, including addiction, depression, and certain types of cancer. Additionally, drugs that can inhibit the activity of other cytochrome P450 enzymes have been shown to be effective in treating a wide range of conditions, including heart disease, diabetes, and certain types of cancer.

In conclusion, TBXAS1 is a potential drug target and biomarker for the inhibition of cytochrome P450 enzyme-mediated drug responses. The inhibition of the activity of this enzyme has been shown to be effective in treating a variety of conditions, including addiction, depression, and certain types of cancer. Further research is needed to fully understand the role of TBXAS1 as a drug target and biomarker, and to develop effective treatments for a wide range of diseases.

Protein Name: Thromboxane A Synthase 1

Functions: Catalyzes the conversion of prostaglandin H2 (PGH2) to thromboxane A2 (TXA2), a potent inducer of blood vessel constriction and platelet aggregation (PubMed:8436233, PubMed:11297515, PubMed:9873013, PubMed:11097184, PubMed:24009185, PubMed:22735388). Cleaves also PGH2 to 12-hydroxy-heptadecatrienoicacid (12-HHT) and malondialdehyde, which is known to act as a mediator of DNA damage. 12-HHT and malondialdehyde are formed stoichiometrically in the same amounts as TXA2 (PubMed:11297515, PubMed:9873013, PubMed:22735388). Additionally, displays dehydratase activity, toward (15S)-hydroperoxy-(5Z,8Z,11Z,13E)-eicosatetraenoate (15(S)-HPETE) producing 15-KETE and 15-HETE (PubMed:17459323)

The "TBXAS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TBXAS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets